Clinical Trial

TremelImumab aNd Durvalumab For the Non-operatIve Management (NOM) of MSI-high Resectable GC/GEJC.

Study acronym: INFINITY
Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
INFINITY is a Phase II, multicentre, single-arm, multi-cohort trial aimed at evaluating the activity and safety of the combination of tremelimumab and durvalumab as neoadjuvant (Cohort 1) and definitive (Cohort 2) treatment for MSI-high gastric/gastroesophageal juction cancer patients eligible for radical surgery.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2021-03-23; most recent amendment 2025-06-05.
Status change: Recruiting → Active, Not Recruiting 2025-02-13
Status change: Not Yet Recruiting → Recruiting 2021-05-06
Trial Details
NCT Number NCT04817826
Lead Sponsor Gruppo Oncologico del Nord-Ovest
Conditions Gastric Cancer, Microsatellite Instability
Enrollment 31 participants
Start Date 2021-04-01
Primary Completion 2025-04-30 (estimated)
Study Completion 2026-04-30 (estimated)
Updated on ClinicalTrials.gov 2025-06-10